Neurodegenerative Disorder Market Expected to Reach US$ 6.8 Billion with a 6.7% CAGR by 2033

The Neurodegenerative Disorder Market in United State is set to undergo robust growth, boasting a projected compound annual growth rate (CAGR) of 6.7%, and is expected to attain a valuation of US$ 1.1 billion by 2033. The increasing elderly population is poised to contribute to the upswing in neurodegenerative disorder prevalence. Market expansion within the nation is foreseen to be fueled by heightened funding for research initiatives targeting neurodegenerative diseases and advancements in the early detection of neurological conditions.
According to Fact.MR's analysis, the global neurodegenerative disorder market is on the brink of substantial growth, with its estimated value projected to surge from US$ 3.6 billion in 2023 to a significant US$ 6.8 billion by 2033. This anticipated expansion is underpinned by a steady increase in global revenue from neurodegenerative disorder therapies, expected to maintain a compound annual growth rate (CAGR) of 6.7% from 2023 to 2033.

Download a Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8634

Neurodegenerative disorders, a class of diseases characterized by the progressive degeneration of the nervous system, have long posed significant challenges to healthcare providers and researchers. Conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) affect millions of individuals worldwide and have been associated with significant human suffering and high healthcare costs. However, recent years have witnessed remarkable breakthroughs in the management of neurodegenerative disorders, offering new hope for patients and their families.

Precision Medicine and Personalized Therapies

A significant leap in the management of neurodegenerative disorders has been marked by the adoption of precision medicine. Researchers now possess a deeper understanding of the genetic and molecular foundations of these diseases, enabling the development of more targeted and personalized treatment approaches. This departure from a generic, one-size-fits-all method to tailored therapies has resulted in improved outcomes and reduced side effects for patients.

Shifting Focus to Disease-Modifying Therapies

Traditionally, treatments for neurodegenerative disorders concentrated on managing symptoms rather than addressing the root causes of these conditions. Recent breakthroughs have ushered in a new era of disease-modifying therapies designed to slow or even halt the progression of these diseases. Clinical trials exploring drugs targeting beta-amyloid and tau proteins in Alzheimer's disease, for example, show promising results, potentially altering the course of the disease.

Dynamic Competitive Landscape

In the global neurodegenerative disorders market, numerous companies are making substantial investments in research and development efforts. Key players frequently deploy strategies such as mergers, acquisitions, and portfolio expansions. Market leaders are also embracing innovative approaches, incorporating new advancements and unique marketing strategies to enhance their market presence.

Recent Noteworthy Developments

In a significant announcement in September 2022, Amylyx Pharmaceuticals revealed that the FDA had granted approval for RELYVRIO, a medical treatment for adults with amyotrophic lateral sclerosis (ALS), comprising sodium phenylbutyrate and taurursodiol.

Additionally, in January 2021, Mitsubishi Tanabe Pharma America, a U.S. subsidiary of the parent company, entered into a license and supply agreement with Aquestive Therapeutics Inc. to secure the rights for Riluzole oral film in the United States. This therapeutic agent is specifically designed for ALS, showcasing the ongoing commitment to advancing treatments in the neurodegenerative disorders landscape.

Key Segments of Neurodegenerative Disorder Industry Research

• By Diagnosis & Treatment :
o Diagnosis
 Inpatient
 Outpatient
o Treatment
 Drugs
 Riluzole
 Edaravone
 Therapy
 Breathing & Feeding Care
 Physical Therapy
 Occupational Therapy
 Speech Therapy
 Assistive Technology Devices
 Brain-computer Interfaces
 Human-computer Interfaces
 Speech Generating Devices
 Communication Boards and Symbol Devices
 Other Assistive Devices

• By Indication :
o Amyotrophic Lateral Sclerosis (ALS)
o Locked-in Syndrome (LIS)

• By Distribution Channel :
o Hospitals Pharmacies
o Retail Pharmacies
o Drug Stores
o Online Pharmacies
o e-Commerce
o Supermarkets

• By Service Provider :
o Hospitals
o Specialty Clinics
o Rehabilitation Centers
o Home Care Settings
o Nursing Care Settings
o Diagnostic Centers

• By Region :
o North America
o Latin America
o Europe
o South Asia
o East Asia
o Oceania
o Middle East and Africa

Get Customization on this Report:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8634

The neurodegenerative disorder market is currently witnessing a transformative phase with breakthroughs in disease management. These developments are offering renewed hope for patients and their families who have long grappled with the devastating effects of these conditions. As researchers continue to unravel the mysteries of these disorders, it is increasingly likely that new and more effective therapies will emerge, ultimately changing the landscape of neurodegenerative disorder management. These innovations represent a beacon of hope in the quest for improved quality of life and a potential cure for those affected by these debilitating diseases.

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.